Prognostic value of upar forms in colon and breast cancer

Projektinformationen

TIMO PIIRONEN

ID Finanzhilfevereinbarung: QLK4-CT-1999-51464

Projekt abgeschlossen

Startdatum 1 August 2000

Enddatum 31 Juli 2002

Finanziert unter

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Gesamtkosten € 143 952,00

EU-Beitrag € 143 952,00

Koordiniert durch

COPENHAGEN UNIVERSITY HOSPITAL
Denmark

Ziel

Investigation of the clinical prognostic value of soluble urokinase plasminogen activator receptor (uPAR) forms in blood and tissue extracts from patients with colon and breast cancer, aiming to develop new methods which will aid in the decision-making needed in the management of cancer patients.

Wissenschaftliches Gebiet

Not validated

• medical and health sciences › clinical medicine › oncology › breast cancer

Programm/Programme

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thema/Themen

• 1.1.1.-4. - Key action Environment and Health

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

RGI - Research grants (individual fellowships)

Koordinator

COPENHAGEN UNIVERSITY HOSPITAL

• EU-Beitrag: Keine Daten
• Adresse: Stransboulevarden 49 ; 2100 KOEPENHAGEN ; Dänemark
• Gesamtkosten: Keine Daten